Glucagon-like peptide-1 agonist
Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes.[1] One of their advantages over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.[2]
There is some concern over the safety profile of these drugs due to proliferative effects in the pancreas.[3]
Approved GLP-1 agonists:
- exenatide (Byetta/Bydureon), approved in 2005/2012
- liraglutide (Victoza, Saxenda), approved 2010[4]
- lixisenatide (Lyxumia), approved in EU 2013[5]
- albiglutide (Tanzeum), approved in 2014 by GSK[6]
- dulaglutide (Trulicity), approved in 2014 - manufactured by Eli Lily K[7]
Under investigation: [1]
- taspoglutide, phase III halted Sept 2010,
These agents work in the same pathway as DPP-4 inhibitors but are generally considered more potent.[8]
References
- 1 2 Baggio LL (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". Medscape Diabetes & Endocrinology.
- ↑ "Standards of medical care in diabetes--2012". Diabetes Care. 35 Suppl 1: S11–63. 2012. doi:10.2337/dc12-s011. PMC 3632172. PMID 22187469.
- ↑ Schweizer M, Perencevich E, McDanel J, Carson J, Formanek M, Hafner J, Braun B, Herwaldt L (2013). "Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis". BMJ 346: f2743. doi:10.1136/bmj.f2743. PMC 3681273. PMID 23766464.
- ↑ "FDA Approves New Treatment for Type 2 Diabetes".
- ↑ "Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA".
- ↑ "FDA Approves Weekly Injectable Diabetes Drug: Albiglutide".
- ↑ "FDA Approves Weekly Injectable Diabetes Drug: Dulaglutide".
- ↑ "GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes".
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, July 05, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.